Evidence map›Paper›PMID 36093086›Full record

ArticleFrontiers in endocrinology2022

Toll-like receptor signaling pathway triggered by inhibition of serpin A1 stimulates production of inflammatory cytokines by endometrial stromal cells.

Kazuya Kusama, Ayaka Satoyoshi, Mana Azumi, Mikihiro Yoshie, Junya Kojima, Yumi Mizuno, Masanori Ono, Hirotaka Nishi, Takeshi Kajihara, Kazuhiro Tamura

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kazuya KusamaDepartment of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Ayaka SatoyoshiDepartment of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Mana AzumiDepartment of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Mikihiro YoshieDepartment of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Junya KojimaDepartment of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
Yumi MizunoDepartment of Obstetrics and Gynecology, Saitama Medical University, Saitama, Japan.
Masanori OnoDepartment of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
Hirotaka NishiDepartment of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
Takeshi KajiharaDepartment of Obstetrics and Gynecology, Saitama Medical University, Saitama, Japan.
Kazuhiro TamuraDepartment of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Tokyo University of Pharmacy and Life Sciences · JPTokyo Medical University · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometriosis is characterized by the presence of inflamed and fibrotic endometrial tissue outside the uterine cavity. Previously, we found decreased SERPINA1 (alpha-1 antitrypsin) expression in endometriosis-like lesions in a mouse model of endometriosis, suggesting that it exacerbated inflammation in these lesions. However, the molecular mechanism(s) by which SERPINA1 affects expression of inflammatory factors and development of endometriotic lesions have not been fully characterized. To investigate the role of intracellular SERPINA1 in endometrial stromal cells (ESCs), we performed RNA sequence analysis using RNA extracted from ESCs in which SERPINA1 was knocked down. The analysis identified several toll-like receptor (TLR)-related factors as being upregulated. Silencing of SERPINA1 increased expression of TLR3 and TLR4 in ESCs, as well as several TLR signaling pathway components, including MYD88, IRAK1/4, interleukin (IL)-1β, and interferon (IFN)-β. TLR3 or TLR4 agonists increased expression of inflammatory factors in SERPINA1-knockdown ESCs, whereas TLR3 or TLR4 inhibitors decreased expression. In addition, treatment with recombinant IL-1β or IFN-β increased expression of MYD88 and inflammatory factors in ESCs. Immunohistochemical analysis of endometriotic tissues showed that TLR3, TLR4, and MYD88 were localized in endometriosis lesions. Taken together, the data suggest that reduced expression of SERPINA1 induces expression of inflammatory factors by ESCs, which in turn are associated with TLR3/4, IL-1β, and IFN-β signaling. Regulation of intracellular SERPINA1 levels in ESCs may be a strategy to inhibit inflammatory responses in endometriotic lesions.

Indexed as

CytokinesEndometriosisAdaptor Proteins, Signal Transducingalpha 1-AntitrypsinAnimalsFemaleHumansMiceMyeloid Differentiation Factor 88Signal TransductionStromal CellsToll-Like Receptor 3Toll-Like Receptor 4Toll-Like ReceptorsAdaptor Proteins, Signal Transducingalpha 1-AntitrypsinCytokinesMyeloid Differentiation Factor 88Toll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptorsalpha-1 antitrypsinendometrial stromal cellsendometriosisinterferon betainterleukin-1 betaserpin A1toll-like receptor

Identifiers

PMID36093086
PMCPMC9448891
OpenAlexW4292877662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.